COVID-19 vaccine hesitancy and influential factors among Thai parents and guardians to vaccinate their children

Kitro, Amornphat; Sirikul, Wachiranun; Dilokkhamaruk, Ekkamon; Sumitmoh, Gowgeat; Pasirayut, Sarisa; Wongcharoen, Amnart; Panumasvivat, Jinjuta; Ongprasert, Krongporn; Sapbamrer, Ratana

doi:10.1016/j.jvacx.2022.100182

Cited by 19 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there were no approved COVID-19 vaccines for children under 18-year-old available in Thailand at that time. Moreover, parental hesitancy to vaccinate their young children against COVID-19 in Thailand remained high, especially in children younger than the age of 12, which was higher than children over the age of 12 (56.9% vs. 17.1%) [ 29 ]. While the study in China has proven the vaccine safety in children over age of 3 [ 30 ], thus we chose to conduct a clinical trial in children from 10–17 years of age, aiming to demonstrate the safety profile of the COVID-19 vaccine, and to evaluate the risk factors and incidence of SARS-CoV-2 infection after BBIBP-CorV administration in a younger age group.…”

Section: Discussionmentioning

confidence: 99%

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand

et al. 2022

View full text Add to dashboard Cite

Coronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10–17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21–28 days apart. To assess vaccine safety, 36,808 participants were then followed with paper- and web-based online questionnaire surveys that captured local and systemic reactogenicities following vaccine administration on days 1, 7, and 30. Among participants, 76% (27,880) reported reactogenicity within the first 24 h and 7 days following the first dose. Half (51.41%) of participants experienced pain at the injection site; the majority of cases were mild in severity. Injection site tenderness (37.93%) was another common local reaction. Fatigue (37.89%), myalgia (33.56%), and headache (26.76%) were the most common systemic reactions. On days 2–7 after the first dose, 25.85% of participants experienced adverse reactions. Following the second dose, reactogenicity was 7.6% and 1.09% within 24 h and between days 2–7. The majority of reactions were of mild to moderate severity. We report that two doses of the BBIBP-CorV caused mild to moderate side effects in adolescents in Thailand. The findings confirm the vaccine’s safety profile in this age group.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Our study revealed that adolescents might need a lower dose to achieve an equal immunogenicity and vaccine effectiveness. A study in Thailand showed that the two most serious concerns for parents influencing COVID-19 vaccine acceptance are about vaccination side effects and safety [ 20 ], which is similar to a meta-analysis study where 61% of parents were concerned about safety of vaccines [ 21 ]. Moreover, using an epidemiological model, fractional dosing has been shown to accelerate vaccination coverage by relieving vaccine resource constraints and reducing mortality [ 22 ].…”

Section: Discussionmentioning

confidence: 75%

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents

et al. 2022

View full text Add to dashboard Cite

Primary series vaccination with BNT162b2 followed by a booster 5 months later has been recommended for healthy adolescents. We aimed to describe the immunogenicity in a fractional dose of BNT162b2. Adolescents aged 12–18 years were randomized into six arms for primary series administration: 3wPZ30/30 (reference group), 3wPZ30/20, 3wPZ20/20, 6wPZ30/30, 6wPZ30/20, and 6wPZ20/20 µg. A booster was given at 5 months after the second dose using either 10 or 15 µg of BNT162b2. Immunogenicity following vaccination was determined by IgG against receptor-binding domain (anti-S-RBD IgG;BAU/mL), surrogate virus neutralization test (sVNT;%inhibition) and pseudovirus neutralization (pVNT;ID50) against Omicron. Non-inferiority criteria were defined as a lower boundary of the geometric mean ratio (GMR) being greater than 0.67. From September to October 2021, 118 adolescents with a median age (IQR) of 14.9 years (13.9–16.7) were enrolled. Fourteen days after the primary series, the geometric means (GMs) of anti-S-RBD IgG (BAU/mL) were 3090 (95%CI 2761–3460) in 3wPZ30/30. The GMRs of anti-S-RBD were: 0.80 (95% CI 0.67–0.97) in 3wPZ30/20; 1.00 (95%CI 0.83–1.20) in 3wPZ20/20; 1.37 (95% CI 1.13–1.65) in 6wPZ30/30; 1.24 (95% CI 1.02–1.50) in 6wPZ30/20; and 1.36 (1.13–1.64) in 6wPZ20/20. After a booster dose with 15 ug (n = 24) of BNT162b2, sVNT and pVNT against Omicron variant were 91.6 (95%CI 88.4–94.9) and 331 (95% CI 221–495), respectively. In the group that received 10 µg of BNT162b2 (n = 25), sVNT was 85.6 (95%CI 80.0–91.6) and pVNT was 397 (95%CI 267–590). Healthy adolescents had good immune responses to the fractional dose regimen of BNT162b2 and this may be considered as an alternative option.

show abstract

“…Knowledge of booster doses and trusting attitudes were the main factors for increasing the uptake rate of COVID-19 booster doses in these areas. Hence, an effective booster dose campaign with an education program on effectiveness and safety to increase attitude levels on booster vaccination should be implemented to increase the COVID-19 booster dose vaccinations throughout the country and increase the resilience performance of COVID-19 prevention and control [ 65 ].…”

Section: Discussionmentioning

confidence: 99%

Combined Impact of Omicron Vaccination and Environmental Risk Exposure: A Thailand Case Study

et al. 2023

View full text Add to dashboard Cite

This research aimed to determine the levels of COVID-19 booster dose vaccinations in Thai populations in areas with environmental risk exposure during the Omicron outbreak. Five of twenty provinces in Thailand were selected by assessing environmental risk exposure for study settings. A total of 1038 people were interviewed by a structured questionnaire. The predicting factors of COVID-19 booster dose vaccinations were analyzed by univariate and multivariate analysis. The results showed that 69.4% (95% CI 66.5–72.1) of the population was vaccinated with COVID-19 booster doses. Multiple logistics regression revealed that the female gender (AOR 1.49, 95% CI 1.11–2.00), all age groups from 38 to 60 years old, all education levels of at least secondary school, high income (AOR 1.16, 95% CI 1.15–2.24), populations having experience with COVID-19 infection (AOR 2.27, 95% CI 2.05–3.76), knowledge of vaccine (AOR 1.78, 95% CI 1.11–2.83), and trusting attitude (AOR 1.76, 95% CI 1.32–2.36) were factors among those more likely to take COVID-19 booster dose vaccinations in high-environmental-risk-exposure areas. Therefore, an effective booster dose campaign with education programs to increase attitudes toward booster vaccinations should be implemented for the resilience of COVID-19 prevention and control.

show abstract

COVID-19 vaccine hesitancy and influential factors among Thai parents and guardians to vaccinate their children

Cited by 19 publications

References 31 publications

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents

Combined Impact of Omicron Vaccination and Environmental Risk Exposure: A Thailand Case Study

Contact Info

Product

Resources

About